Cotadutide

Cotadutide is a dual GLP-1/glucagon receptor agonist being developed for metabolic dysfunction-associated steatohepatitis, obesity, and type 2 diabetes. It aims to improve glucose control and suppress appetite.

In the literature, Cotadutide appears most often in work focused on fat loss, weight loss and blood sugar. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.

Because it is catalogued here under powder peptides, Cotadutide also shows up in discussions of metabolism. Coverage across those topics varies widely in quality and depth, and much of it is early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.